Table 1.

Baseline Characteristics

	Suspected Gastroparesis N=150 subjects
Age, median (IQR)	44.5 (22.8)
Female gender, n (%)	118 (78.7)
BMI (kg/m2), median (IQR)	27.2 (10.7)
Etiology, n (%)
Diabetic	43 (28.7)
Non-Diabetic	107 (71.3)
Infectious prodrome, n (%)	17 (11.3)
Duration of symptoms (months), median (IQR)	36 (53.5)
Marijuana use, n (%)	11 (7.3)
Opioid use, n (%)	18 (12.0)
Rome III criteria for FBD, n (%)	117 (80.7)
Predominant constipation symptoms	52 (36.4)
Predominant diarrhea or mixed-type bowel symptoms	91 (63.6)
Rome III criteria for FD, n (%)	109 (75.7)
Rome III criteria for N/V/Belching Disorders, n (%)	86 (59.7)
Baseline BSFS (range 1–7), median (IQR)	4.0 (3)
Delayed GES, n (%)
>60% retention at 2h	16 (10.7)
>10% retention at 4h	36 (24.2)
Severely delayed GES (> 35% retention at 4h), n (%)	11 (7.4)
Delayed GET, n (%)	53 (35.6)
Severely delayed GET (GET > 12h), n (%)	21 (14.1)
Delayed SBTT, n (%)	33 (22.6)
Delayed CTT, n (%)	45 (30.8)
Generalized transit delay (transit delays in ≥2 regions), n (%)	17 (11.6)
Global transit delay (transit delays in all 3 regions), n (%)	8 (5.5)
Gastric Ct, median (IQR)	48.0 (59.5)
Gastric MI, median (IQR)	11.4 (2.5)
Small bowel Ct, median (IQR)	111.0 (127.5)
Small bowel MI, median (IQR)	12.6 (2.7)

BMI, body mass index; BSFS, Bristol Stool Form Scale; Ct, contraction frequency; CTT, colonic transit time by wireless motility capsule; FBD, functional bowel disorder by Rome III criteria; FD, functional dyspepsia by Rome III criteria; GES, gastric emptying scintigraphy; GET, gastric emptying time by wireless motility capsule; MI, motility index; N/V/Belching, functional nausea/vomiting and/or belching disorder by Rome III criteria; SBTT, small bowel transit time by wireless motility capsule.